Compare Johnson & Johnson (JNJ) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Toyota Motor Corp — how do they compare? Johnson & Johnson trades at $259.01 (market cap $618.09B), while Toyota Motor Corp trades at $184.87 (market cap $217.38B). The key difference: Johnson & Johnson is far larger — about 2.8× Toyota Motor Corp's market cap, and Toyota Motor Corp pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Toyota Motor Corp for 116 Days on average.
| JNJ | TM | |
|---|---|---|
Market Cap | $618.09B | $217.38B |
Volume | 6,050,983 | 291,250 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $248.29 |
52-Week Low | $186.00 | $166.50 |
Typical Hold Time | 129 Days | 116 Days |
Enterprise Value | $646.37B | $410.96B |
Dividend Yield | 2.09% | 3.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Toyota Motor trades at $185.17, up 1.24% with a bearish technical signal despite strong fundamentals. The stock shows attractive valuation metrics with a P/E of 8.38 and P/S of 0.73, while delivering consistent earnings beats in recent quarters. Recent news highlights strong U.S. sales performance and electrification progress, though technical indicators show selling pressure with key support at $184.
Toyota presents a value opportunity with solid profitability and clean balance sheet, though near-term headwinds include China sales weakness and production disruptions. Analyst consensus leans cautious with 62.5% hold ratings, reflecting concerns about profit margin compression despite the company's market leadership and electrification investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
